An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease On Nov. 6, Bayer announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA® (finerenone) significantly reduced urine albumin-to-creatinine...
A major shift is underway in women’s endocrine health that is changing how the medical community approaches Polycystic Ovary Syndrome (PCOS) and its link to cardiovascular risk. Recent findings published in the European Journal of Endocrinology, titled “Hyperandrogenaemia, Polycystic Ovary Syndrome, and Physical Fitness in Women—a Northern Finland Birth Cohort Study,” stem from a large...
The safety profile of zoledronic acid (ZOL), a powerful bisphosphonate widely used for osteoporosis and metastatic bone diseases in cancer patients, has historically been regarded as well-established. Common side effects such as fever, myalgia, and flu-like symptoms are manageable and transient. However, a recent case report in the JCEM Case Reports journal highlights a rare...
For patients with large, symptomatic thyroid goiters and toxic nodules, the question of whether to undergo surgery may soon have a less invasive answer. A new procedure, pressure-enabled thyroid embolization (PED-TAE), is emerging as a promising alternative. An initial clinical study published in the Journal of the Endocrine Society titled, “Safety and Efficacy of Pressure-Enabled...
Prescription Drug Pricing Update: Society Continues Advocacy to Lower Price and Out-of-Pocket Costs of Medications Last month, the Trump Administration and a major retailer took steps to address high prescription drug prices. On September 30, the Trump Administration announced the creation of “TrumpRx,” a consumer website where Americans can buy medications at a discounted price....
While I think every issue of Endocrine News is intriguing, this month’s issue really piqued my interest because it focuses on the atypical and unusual: rare endocrine diseases. From Cushing’s syndrome to hypoparathyroidism and more, we’ve endeavored to include as many endocrine disorders as possible that might tend to be “off the beaten path,” so...
Emerging technologies and innovative equipment are prioritizing comfort in endocrine laboratories, enhancing both efficiency and staff well-being. Endocrine labs demand intense focus and precision, but long hours at the bench can lead to fatigue, strain, and reduced efficiency. Today’s lab equipment manufacturers are addressing these challenges with innovative products designed to improve ergonomics and overall...
As an eager student in his native Ghana, Theophilus Tettey, PhD, saw firsthand how classroom theories had real-world implications. Now, as a researcher at the National Cancer Institute, he hopes to one day create a laboratory that thrives on working across disciplines while providing a welcoming environment for up-and-coming scientists. Growing up in Ghana, West...
The safety profile of zoledronic acid (ZOL), a powerful bisphosphonate widely used for osteoporosis and metastatic bone diseases in cancer patients, has historically been regarded as well-established. Common side effects such as fever, myalgia, and flu-like symptoms are manageable and transient. However, a recent case report in the JCEM Case Reports journal highlights a rare...
For patients with large, symptomatic thyroid goiters and toxic nodules, the question of whether to undergo surgery may soon have a less invasive answer. A new procedure, pressure-enabled thyroid embolization (PED-TAE), is emerging as a promising alternative. An initial clinical study published in the Journal of the Endocrine Society titled, “Safety and Efficacy of Pressure-Enabled...
